US FDA issues guidance on development of stimulant use disorder drugs
The new draft guidance reveals the US regulator’s current views on developing drugs and biologics for stimulant use…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Oct 23
The new draft guidance reveals the US regulator’s current views on developing drugs and biologics for stimulant use…
05 Oct 23
As per the results from the Phase 1/2 study, the vaccine was found effective against all four A…
05 Oct 23
Under the collaboration, both firms will co-develop and co-commercialise Teva's anti-TL1A drug, TEV’574 asset, which is currently in…
05 Oct 23
The funding round was spearheaded by Kurma Partners' Growth Opportunities Fund, with active involvement from established investors like…
05 Oct 23
The second IDE Study will be conducted for the safety and efficacy for the treatment of knee OA…
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
04 Oct 23
The expanded collaboration combines Intellia’s genome editing platform with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to develop…
04 Oct 23
The collaboration aims to facilitate KateTx's initial internal portfolio of gene therapy programmes focused on muscle and heart…
04 Oct 23
The potential development program reflects PharmaEssentia’s efforts to diversify its current expertise and expand its pipeline with a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates